There are other situations where products more effective and safer than FFP are available for correction of coagulopathy, such as, recombinant or virally inactivated specific clotting factor concentrates, for treatment of hemophilia, von Willebrand's disease, and hypofibrinogenemic states, and prothrombin complex concentrates and vitamin K for warfarin reversal.[10]. This evidence concerns the gene F2 and platelet-type von Willebrand disease.